Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Flash
I respect your decision to exit if that is your investment decision.
However with the confirmation by the company of moving straight to a Phase 3 trial for Lupuzor, the appointment of a CRO and the continuing funding commitment from Alora /Avion, Immupharma is now a c£6m market cap minnow with a potential blockbuster drug in final stage trials after exhaustive and detailed discussions and guidance from the FDA on how best to navigate the trial for an optimal result.
Throw in CIPD where it is presumed will now enter a Phase 3 as well supported either by Avion or another partner then it is clear to me that Immupharma now has a value greatly in excess of its current market cap notwithstanding the length of the trials.
It is all about the first dosing of patients in the trials as a major catalyst for the share price and I hope a rest of the world partnership for Lupuzor and a full rights for CIPD will be announced in the coming months.
I expect interest in these partnerships to have been heightened as a result of the formal appointment of the CRO and confirmation of the Alora Groups continued support .
The presence of Lanstead is currently a drag on the share price but this can be easily resolved with additional positive newsflow.
I feel Immupharma is now an interesting corporate play for a larger Pharma and maybe Alora may be tempted to takeover the entire company.
Also the Incanthera deal with A.S. Watson part of the massive Group could see an unexpected return for Immupharma in 2024.
Anyway best of luck
DYOR
C K Hutchinson
Superb update today.
New founded entities established to fund and drive forward some of Puretech's wholly owned therapies thereby releasing funds for shareholders.
Special dividend and/or share buybacks to be announced.
Sale of remaining 2.4% equity interest in Karuna looks likely in the near term releasing c $200m for distribution to shareholders.
Vedanta progressing very well and could be next Karuna with multi billion valuation with c 47% shareholding held by Puretech.
Other founded entities, apart from Gelesis , moving along and the wholly owned drugs being kept in house by Puretech could be blockbusters after trial results later in 2024.
All in all fantastic news and validates everything I have said in my previous posts.
As usual the UK Stock Market hasn't responded in terms of an uplift in the Puretech share price...maybe Nasdaq will.
ATB
Nolupus
Septic tanks rhyming slang for Yanks..you could be right and maybe more news from the US very shortly with Dr O'Reilly on board.
Excellent analysis once again , Nolupus.
You may be tempted some day to buy a few shares.
Now that would be a major bull signal.
ATB
Flash
Agreed but Immupharma and Avion arrangement reaffirmed and Lupuzor trial is now a Phase 3 rather than a longer Phase 2/3 trial.
This greatly enhances the value of Immupharma as there are very few AIM Pharma minnows progressing a Multi billion $ drug in a Phase 3 trial.
My hope is that Immupharma will be bought out now as the Lupuzor trial gets underway.
A disastrous RNS would have been Alora/Avion walking away and now we are a Phase 3 trial with them.
So despite the infuriating delays I am feeling better about the state of Immupharma today.
Definitely sets a floor on the SP and may now attract some large buyer interest into.
ATB
Pokerchips
I am thinking something much more strategic than this so called distribution agreement which I found somewhat strange to be honest given Immupharma is
staffed by a few people in the UK and a research facility in France.
Also Immupharma has minimal cash resources to get involved in distribution so not expecting much in this regard.
Tim playing games again ?
Flash
I understand your concerns which I share but Dr Laurence O'Reilly is not going to join the board of an AIM listed minnow without doing significant due diligence and seeing opportunities.
Also I see the hidden hand of Art Deas, the CEO and large shareholder of the Alora group behind his appointment imho which if it is the case could signify something more strategic coming down the tracks between Immupharma and Alora/ Avion
Hopefully!!!
Dr O'Reilly is Vice President of Research and Investments for Royalty Pharma, a Nasdaq listed $18 billion market cap company.
How did we all miss this as being massive as O'Reilly wouldn't dream of joining Immupharma unless big things were about to happen particularly in an £7m AIM market cap company.
Very reassuring imho.
ATB
Wow how did I miss the connection between Dr Laurence O'Reilly and Royalty Pharma who have done a mega deal with my other major Pharma investment, Puretech Health.
Royalty Pharma bought the royalties from Puretech in relation to its investment in Karuna for $500m ( $100m paid upfront) and the balance payable on FDA approval of Karuna drug for schizophrenia expected in the next 6 months.
Karuna is valued at $8billion on Nasdaq .
O'Reilly is some serious player.
Great news for Immupharma imho.
Cauldstream
Agree but McCarthy and the new Directors can still get on with negotiating the Rest of the World rights for Lupuzor plus the total World rights for CIPD.
However I suspect these negotiations probably depend on what Alora/ Avion decide.
All to play for.
Cauldstream
Agreed
When shares like Immupharma move they can move fast and in big volumes particularly if the TikTok punters arrive in force like with Ethernity where 10 times the issued share capital was traded in a week while before the herd arrived you would be lucky to see 5 trades a day .
Hopefully this will happen in Immupharma as well but
firstly some news , Mr McCarthy, please.
Flash
I was thinking the same thing.
Only significant positive newsflow will allow Lanstead to offload and give the share price a chance to rise.
It happened in Ethernity Networks a month or two ago when the SP rose by 18 times and helped clear out another vulture fund who had a vice like grip on the share.
The oily McCarthy is not in any hurry to update the market and so any buying is only feeding Lanstead.
It's been a long 8/9 years of struggle with Immupharma and we could all do with some Christmas cheer.
ATB
Grezzz,
Please see some of my recent posts here.
Furthermore I have been in communication with Kana DeLuca of Puretech's Investor Relations regarding the total disconnect between the share price and the company's assets and she confirmed the Board's concern that this clear undervaluation is not recognised by the market and she referred me to the recent RNS regarding Capital allocation and investors returns and some further announcements on these plans are expected soon.
She recognised that the market cap of the company is but a small fraction of the sum of the parts valuation of Puretech and this is being addressed notwithstanding the general market apathy towards Bio tech companies.
For example she cited one of Puretech's own drugs, LYT-100 for pulmonary fibrosis which is in Phase 2B trials and for which headline results are expected in 2024 .
Kana says LYT-100 could be a $billion blockbuster drug and is one of a number within the own in-house suite of drugs which is potentially transformational.
I noted that Karuna Therapeutics, the $8billion Nasdaq listed company founded by Puretech, is a clear case in point of Puretech's ridiculous market cap of c£400m ....Puretech's 3.1% shareholding in Karuna is valued at c$250m plus royalties sold for $500m ( $100m already received and the balance on FDA approval for KartX , Karuna's blockbuster Schizophrenia drug, which is almost certain over the next months) , milestone payments of c$50m plus and other royalties in excess of a certain amount ,total up to almost $800m in real cash against Puretech's market cap of c$500m and ignoring everything else including Puretech's cash $350m and own drugs plus founded entities particularly Vedanta which is a potential multi billion $ company and where Puretech owns 40% of the equity.
Even today Puretech should be valued at around £1-1.5 billion or c4.5 /5 a share and much higher in 12 months time imho .
I am going to buy more , funds permitting, over coming weeks.
Finally I encourage you all to contact Kana by email and to confirm what I have said above and any other questions you may have.
Cheers and ATM
Wildbunch
Here is your mad mate..here for 8 years and have 3m shares at 9p average.
As I have said before I have a large investment in Puretech whose founded listed entity ,Karuna Therapeutics developed one of Puretech's schizophrenic drugs and passed Phase 3 trials and is awaiting FDA approval to market it.
Karuna is valued on the Nasdaq at $8b .
The global market for Lupus and CIPD therapies is greater than for schizophrenic drugs so it just demonstrates the prize for Alora/Avion and Immupharma if they can navigate through the trials to successfully bring Lupuzor to market.
A big if I agree but the potential is massive.
I think a big rerate is possible if we get confirmation of the start of the trials but Immupharma and Uncle Tim know how to keep investors on tenterhooks.
The enormous amount of data submitted to the FDA over the past 18 months and the FDA's guidance and agreed guidelines for the trial albeit Phase2/3 is pharma gold imho.
Fingers crossed for some positive news.
By the way I hope you are doing well with your treatment and I wish you the best.
Sadly silence on AIM creates fear of bad news.
The SP is now at all time lows so naturally investors are deeply concerned.
The new Directors hopefully will add some business acumen but so far no evidence of anything happening.
Ethernity, another unloved AIM share , going ballistic again as the mad TikTok herd ramp it up on the most naive analysis.
If only they would turn their gaze on poor old Immupharma!
Blue apple
We hope you are right but what other pharma minnow
with a market cap of just c£6/7 million has 2 potential blockbusters with Lupuzor and CIPD drugs at Phase 2/3 trials and other interesting therapies .
I have invested big in Puretech whose founded company ,Karuna , has successfully gone through Phase 3 trials for its schizophrenia drug and awaiting FDA approval and has a market cap of c$6billion.